Bortezomib CAS 179324-69-7 Maʻemaʻe ≥99.0% (HPLC) API Hale Hana Maʻemaʻe Kiʻekiʻe
Hoʻolako i nā mea kikowaena pili Bortezomib me ka maʻemaʻe kiʻekiʻe
(1S,2S,3R,5S)-(+)-2,3-Pinanediol CAS 18680-27-8
(1R,2R,3S,5R)-(-)-2,3-Pinanediol CAS 22422-34-0
Bortezomib CAS 179324-69-7
| Inoa Kimia | Bortezomib |
| Nā huaʻōlelo like | Velcade, MG-341, PS-341 |
| Helu CAS | 179324-69-7 |
| Helu CAT | RF-API65 |
| Kūlana Kūʻai | Ma ka waihona, ʻoi aku ka nui o ka hana a hiki i nā haneli kilogram |
| ʻĀpana Molekala | C19H25BN4O4 |
| Kaumaha Molecular | 384.24 |
| Lae hehee | 122.0~124.0 ℃ |
| ʻO ka mānoanoa | 1.214 |
| Hōʻike Hōʻike | 1.564 |
| Ka hikiwawe | Hiki ke hoʻoheheʻe ʻia i loko o Chloroform, DMSO, Ethanol a me Methanol |
| Paʻa | ʻO Hygroscopic a me ka maʻemaʻe |
| Kūlana Hoʻouna | Hoʻouna ʻia ma lalo o ka wela ambient |
| Brand | Kemika Ruifu |
| 'ikamu | Nā kikoʻī |
| Ka nana aku | Pada keʻokeʻo a i ʻole keʻokeʻo |
| Maʻemaʻe / Kaʻina Hanana | ≥99.0% (HPLC) |
| Nalo ma ka maloo | ≤0.50% |
| Koena ma ka Ignition | ≤0.20% |
| ʻO ka hoʻololi ʻana | -41.0° ~ -46.0° |
| Metala Kaumaha | ≤20ppm |
| ʻakika | 4.0~7.0 |
| Isomer | ≤0.50% |
| Hoʻokahi haumia | ≤0.50% |
| Huina paumaele | ≤1.0% |
| Nā mea hoʻoheheʻe koena | |
| Methanol | ≤0.30% |
| Dichloromethane | ≤0.05% |
| Hexane | ≤0.02% |
| Ethyl Acetate | ≤0.50% |
| Kūlana hoʻāʻo | Kūlana ʻoihana |
| Hoʻohana | API |
Pūʻolo: ʻO ka ʻōmole, ʻeke ʻeke alumini, pahu pahu pahu, 25kg / pahu, a i ʻole e like me ka makemake o ka mea kūʻai aku.
Kūlana mālama:E mālama i loko o nā pahu i hoʻopaʻa ʻia ma kahi maloʻo a maloʻo;Palekana mai ka malamalama, ka ma'ū a me ka pest infestation.
ʻO Shanghai Ruifu Chemical Co., Ltd. ka mea hana nui a me ka mea hoʻolako o Bortezomib (CAS: 179324-69-7) me ke kūlana kiʻekiʻe, API.
ʻO Bortezomib, i kūʻai ʻia ma lalo o ka inoa Velcade ma waena o nā mea ʻē aʻe, he lāʻau anti-cancer i hoʻohana ʻia e mālama i ka myeloma lehulehu a me ka lymphoma cell mantle.Ua ʻae ʻia ʻo Bortezomib no ka hoʻohana ʻana i ka lāʻau lapaʻau ma ʻAmelika Hui Pū ʻIa i ka makahiki 2003 a ma ka European Union ma 2004. Aia ma ka papa inoa o nā lāʻau lapaʻau koʻikoʻi o ka World Health Organization.ʻO Bortezomib ka mea paʻa mua proteasome i ʻae ʻia e ka US FDA no ka myeloma lehulehu, he maʻi maʻi koko.He mea hoʻopaneʻe hiki ke hoʻohuli ʻia o ka 26S proteasome-he ʻāpana multiprotein me ke ʻano o ka pahu i loaʻa i loko o ka nucleus a me ka cytosol o nā cell eukaryotic a pau.ʻO Bortezomib kahi mea koho a paʻa i ka 26S proteasome inhibitor, ʻo ia ka derivative acid boronic dipeptide.Hōʻike nā haʻawina maʻi maʻi pancreatic kanaka iā Bortezomib e kāohi i ka PKR-like endoplasmic reticulum (ER) kinase a hoʻonui i ke koʻikoʻi ER, e alakaʻi ana i ka apoptosis.
